GlassScriptPhysician profile
Michael R Gieske
NPI 1316903636
$9,426.51
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $221 · 2021: $1,477 · 2022: $255 · 2023: $37.29 · 2024: $6,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,889 · Food and Beverage: $586 · Travel and Lodging: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,889.00 |
| Food and Beverage | $585.61 |
| Travel and Lodging | $531.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,229.05 | 2019-2024 | Imfinzi |
| Eli Lilly and Company | $2,825.00 | 2024 | |
| Intuitive Surgical, INC. | $175.57 | 2021-2024 | |
| Body Vision Medical INC. | $173.35 | 2024 | Lungvision |
| Takeda Pharmaceuticals U.S.A., INC. | $146.28 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $121.87 | 2019 | |
| Novo Nordisk INC | $110.59 | 2019-2022 | |
| Amarin Pharma, INC. | $83.82 | 2020-2022 | |
| Abbvie INC. | $72.35 | 2021-2023 | |
| Glaxosmithkline, LLC. | $71.16 | 2019-2022 | |
| Amgen INC. | $61.13 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $45.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $43.33 | 2019-2020 | |
| Lilly USA, LLC | $38.87 | 2019-2024 | Retevmo |
| Allergan, INC. | $29.38 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $27.96 | 2022-2023 | Flexitouch Plus, Entre Plus |
| Daiichi Sankyo INC. | $27.05 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.12 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.73 | 2019 | |
| Genentech USA, INC. | $17.68 | 2019 | |
| Abbott Laboratories | $16.16 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.10 | 2022 | |
| Astellas Pharma US INC | $14.06 | 2021 | |
| Pfizer INC. | $11.03 | 2019 | |
| Dynavax Technologies Corporation | $7.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gieske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.